cfHPV DNA assay
cfHPV DNA represents a promising surrogate of disease burden in patients with HPV-driven cancers. Applying ultra-sensitive technology to detect and quantify circulating HPV-DNA using HPV-SEQ is an innovative and exciting step forward in the development of more targeted approaches when managing HPV-associated cancers. HPV-SEQ has high analytical and clinical sensitivity, with the ability to reliably and consistently detect as low as 2 copies of HPV 16 and HPV 18 DNA.
|Plasma-Safe-SeqS panel||Clinically relevant gene regions||Intended uses|
|HPV-SEQ & HPV-related cancers||HPV 16, HPV 18|
|Cell-free DNA analysis for solid tumors|
|7 – 10 Business days|